Materials and information provided during this presentation may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties that could cause actual outcomes and results to differ materially from these statements.

Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency examination periods and obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.

The Company cannot guarantee the actual outcomes and results for any forward-looking statements.

Furthermore, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.

The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

The English-language presentation was translated from the original Japanese-language version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese-language version shall prevail.
Recap of FY2015 Performance

Growth of global brands and expansion of business in China and Asia
Total revenue from global brands: 63.6B yen (140% YoY)
China revenue: 49.3B yen (120% YoY) Asia revenue: 34.0B (110% YoY)

Selection and focus on businesses with capacity for continued innovation
<Reform of manufacturing sites: transformed from volume based strategy>
August 2015: North Carolina plant in U.S. transferred to Biogen Inc.
April 2016: Pharmaceutical manufacturing and marketing subsidiary, Sannova Co., Ltd., transferred to Alfresa Holdings Corporation

<Transformation of business portfolio>
December 2015: Diagnostics business, EIDIA Co., Ltd., transferred to Sekisui Chemical Co., Ltd.
February 2016: Eisai Food & Chemical Co., Ltd. transferred to Mitsubishi-Kagaku Foods Corporation
March 2016: AkaRx, Inc. transferred to PBM Capital Group, LLC.
April 2016: Establishment of EA Pharma Co., Ltd. through integration of Eisai’s gastrointestinal disease business with AJINOMOTO PHARMACEUTICALS CO., LTD.

Pipeline development based on accelerated disease focused strategy
- **Halaven**: Soft tissue sarcoma*:2 Approved in U.S. (January 2016), Japan (February 2016) and EU (May 2016)
- **LENVIMA**: Thyroid cancer: Launched in U.S. (February 2015), Japan (May 2015) and EU (June 2015)
  - Hepatocellular carcinoma 1st line: Completed enrollment of Phase III study in July 2015
    Submission planned in FY2016
- **Fycompa**: U.S. and EU (June 2015): Achieved additional indication as adjunctive therapy for PGTC
  - Japan (March 2016): Approved as adjunctive therapy for partial-onset and generalized tonic-clonic seizures
- **E2609**: Early AD*:4 Have identified a relevant dose based upon results from all Phase I and Phase II data
- **BAN2401**: Early AD*:4 Phase II interim analysis at 650-patient-randomization
  - IMC*:5 recommended study continuation without any modification toward 700 patients

---

*1: Halaven, LENVIMA, Fycompa and BELVIQ® *2: Approved in U.S. and EU for liposarcoma and Japan for soft-tissue sarcoma *3: Prescription Drug User Fee Act *4: Prodromal AD(Alzheimer’s disease), mild cognitive impairment (MCI) due to AD and others *5: Independent Monitoring Committee
## FY2015 Consolidated Statement of Income (IFRS)

(Billion yen, %)

<table>
<thead>
<tr>
<th></th>
<th>FY2014</th>
<th></th>
<th>FY2015</th>
<th></th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Results</td>
<td>%</td>
<td>Results</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>548.5</td>
<td>100.0</td>
<td>547.9</td>
<td>100.0</td>
<td>100</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>193.6</td>
<td>35.3</td>
<td>194.5</td>
<td>35.5</td>
<td>100</td>
</tr>
<tr>
<td>Gross profit</td>
<td>354.9</td>
<td>64.7</td>
<td>353.5</td>
<td>64.5</td>
<td>100</td>
</tr>
<tr>
<td>R&amp;D expenses</td>
<td>131.9</td>
<td>24.1</td>
<td>122.3</td>
<td>22.3</td>
<td>93</td>
</tr>
<tr>
<td>SG&amp;A expenses</td>
<td>194.5</td>
<td>35.5</td>
<td>192.8</td>
<td>35.2</td>
<td>99</td>
</tr>
<tr>
<td>Other income &amp; expenses</td>
<td>(0.1)</td>
<td>(0.0)</td>
<td>13.6</td>
<td>2.5</td>
<td></td>
</tr>
<tr>
<td>Operating profit</td>
<td>28.3</td>
<td>5.2</td>
<td>51.9</td>
<td>9.5</td>
<td>183</td>
</tr>
<tr>
<td>Profit for the year</td>
<td>43.5</td>
<td>7.9</td>
<td>55.0</td>
<td>10.0</td>
<td>127</td>
</tr>
<tr>
<td>ROE (%)</td>
<td>7.7</td>
<td></td>
<td>9.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dividends (yen)</td>
<td>150</td>
<td></td>
<td>150</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The year for return to growth trajectory in main business

FY2015 average exchange rates: USD: 120.14 yen (+9.3% YoY), EUR: 132.57 yen (-4.5% YoY), GBP: 181.30 yen (+2.6% YoY), RMB: 18.85 yen (+6.3% YoY)
Breakdown of Revenue Migration
Expansion of global brands and steady growth in China and Asia*1

(Billion yen)

Revenue FY2014  Expansion of global brands*2  Expansion of business in China and Asia*3  Pharmaceutical business in Japan  Others  Revenue FY2015

548.5  +15.9  +10.6  −11.6  −15.5  −0.5B yen YoY  547.9

<Major factors for decrease>

♦ Q2 FY2014
  Divestiture of marketing rights of Zonegran in U.S.
  E3710 license agreement with Zeria Pharmaceutical Co., Ltd.
♦ Q4 FY2014
  Epizyme, Inc. milestone payment receipt associated with change of the scope of collaboration

*Figures shown on breakdown of revenue migration are approximate.
*1: Mainly South Korea, Taiwan, Hong Kong, India, and ASEAN
*2: Excluding revenue of pharmaceutical business in Japan
*3: Excluding revenue of global brands
Breakdown of Operating Profit Migration
Growth of global brands, business in China and Asia*1 and execution of strategic options*2

(Billion yen)

<table>
<thead>
<tr>
<th>Operating profit FY2014</th>
<th>Expansion of global brands*3</th>
<th>Expansion of business in China and Asia*4</th>
<th>Pharmaceutical business in Japan*5</th>
<th>Reduction in R&amp;D expenses*6</th>
<th>Other operating profit migrations</th>
<th>Operating profit FY2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>28.3</td>
<td>+29.3</td>
<td>+2.5</td>
<td>-10.7</td>
<td>+9.6</td>
<td>-7.0</td>
<td>+23.6 B yen YoY</td>
</tr>
</tbody>
</table>

<Major factor for increase>
- Execution of strategic options*2
- Q2 FY2014 Divesture of marketing rights of Zonegran in U.S. E3710 license agreement with Zeria Pharmaceutical Co., Ltd.
- Q4 FY2014 Epizyme, Inc. milestone payment receipt associated with change of the scope of collaboration
- Foreign exchange losses

<Major factors for decrease>
- Q2 FY2014 Execution of structural business in U.S.
- Q3 FY2014 Divestiture of U.S. North Carolina plant
- Q3 FY2014 Divestiture of diagnostics business EIDIA Co., Ltd.
- Q4 FY2014 Divestiture of Eisai Food & Chemical Co., Ltd.
- Q4 FY2014 Divestiture of AkaRx, Inc.

*1: Mainly South Korea, Taiwan, Hong Kong, India, and ASEAN
*2: Major factors: Structural reform in U.S. (Q1), divestures of U.S. North Carolina plant (Q2), diagnostics business EIDIA Co., Ltd. (Q3), Eisai Food & Chemical Co., Ltd. (Q4), and AkaRx, Inc. (Q4)
*3: Operation profit of Halaven, LENVIMA, Fycopa and BELVIQ®, except pharmaceutical business in Japan
*4: Segment profit. Excluding profit of global brands
*5: Segment profit
*6: Including reduction in R&D expenses following entry into collaboration with Purdue Pharma L.P. to develop and commercialize lemborexant (Q2)
FY2016: Initial year of EWAY 2025

**Strategic Intent 1**
Accelerate initiatives in dementia field

**Strategic Intent 2**
Pipeline progress of neurology and oncology, including 13 flagship products/compounds

**Strategic Intent 3**
Growth in all regions
Initiatives to Accelerate Development of E2609*¹ and BAN2401*¹

**E2609**

- Importance of BACE inhibition as MOA of next generation AD treatment confirmed by Icelandic Genetic Research*²
- Have identified a relevant dose based upon results from the safety and aggregate PK/PD modeling from all Phase I and Phase II data, and have requested an end of Phase II meeting with FDA to discuss results and Phase III protocol
- Preparing Phase III start-up activities in FY2016

**BAN2401**

- Phase II interim analysis at 650-patient-randomization occurred at the end of March 2016, and IMC*³ recommended study continuation without any modification
- Next interim analysis at 700-patient-randomization is expected to occur in June 2016
- Continue to explore with Health Authorities on how to leverage the ongoing Phase II study in future pivotal programs should the Phase II study achieve positive outcomes

Streamlined development scenarios to minimize number and size of Phase III programs for all assets under consideration by the collaboration, including potential combination opportunities

*1: Investigational. Both compounds are under development with Biogen Inc.
*2: References:
*3: Independent Monitoring Committee
Investigational Lemborexant*1
Orexin receptor antagonist
Maximize potential value as a new insomnia treatment

High need for new insomnia treatment

Sleep disorder in the elderly

GABA$^2$-gated insomnia treatment, one of the major insomnia treatments today, may impact sleep quality, memory impairment, nocturnal awakening, nighttime imbalance and falling, and others impacting the elderly$^3$

Sleep disorder associated with AD

- Sleep-wake fragmentation
- Reduction in nocturnal sleep
- Nocturnal wandering
- Daytime sleepiness

Sleep disorder is one of the clinical concerns in patients with AD as it may accelerate cognitive function decline and burden caregivers

Development status of lemborexant seeking to fulfill patients’ needs

Plan to initiate Phase III study for insomnia in Q1 FY2016

Approx. 40% enrollment will be elderly patients (age 65 years or over) aiming for differentiation from conventional insomnia treatments

Development under preparation for sleep-wake fragmentation in dementia as a potential new indication

Plan to initiate Phase II study in FY2016

*1: Investigational. Co-development with Purdue Pharma  
*2: Gamma-aminobutyric acid  
*3: Sleep proceeds in cycles of REM and NREM. GABA-gated insomnia treatments has an inhibitory effect on REM.
Investigational E2027 PDE9\(^*1\) inhibitor
Aiming for improvement of core symptoms\(^*2\)
and BPSD\(^*3\) in patients with dementia

**E2027 mechanism of action**

**cyclic GMP\(^*4\)**

- Observed as a key role in core symptoms and BPSD

**PDE9**

- Degrading enzyme of cyclic GMP

---

**E2027 Phase I study ongoing**

*Increased cGMP level in cerebrospinal fluid (CSF) by E2027 administration confirmed in Phase I study in healthy adults*

*Pursue potential of improving core symptoms and BPSD in AD and other types of dementia by inhibiting PDE9*

---

\(^*1\): Phosphodiesterase 9
\(^*2\): Memory impairment, impaired judgment, disorientation and others
\(^*3\): Behavioral and psychological symptoms of dementia such as impatience, agitation, aggression, psychological symptom
\(^*4\): Cyclic guanosine monophosphate
Dementia: Social Innovation for the Biggest Challenge in Modern Society

Initiatives toward realization of Prevention, Cure and Care

Aim for next generation AD treatments

- BACE inhibitor E2609*: Phase II study
- Anti A-beta antibody BAN2401*: Phase II Study
- Project targeting Tau: Preclinical

Aim for improvement of symptoms

- Orexin receptor antagonist Lemborexant**: Sleep-wake fragmentation in dementia
  Initiation of Phase II study planned in FY2016
- PDE9 inhibitor E2027: Phase I study

Initiatives for regional healthcare which delivers assurance and safety

Dementia solutions business in Japan

- Provide dementia solution which contributes toward realization of symbiotic society for dementia through collaboration with community healthcare supporters such as doctors, pharmacists, nurses, care workers, care givers/families and others, at 56 dementia coordination partners in Japan
- Contribute to improving the assessment of the level of care required for patients by utilizing smart mobile for multidisciplinary collaboration systems. For example, to improve compliance by an adherence support device. Also to realize a society where patients can go out safely by using support tools

*All projects are investigational  *1: Co-development with Biogen Inc.  *2: Co-development with Purdue Pharma
Halaven
Chemotherapy confirmed OS*1 extension in monotherapy from multiple large-scale clinical trials in patients with refractory breast cancer and soft tissue sarcoma

Aim to establish position as microenvironment modulator leveraging approval of new additional indication for soft tissue sarcoma*2

U.S. and Japan: Approved in Q4 FY2015
EU: Approved on May 2, 2016

Phase III study with 530 patients with metastatic breast cancer (Study 304) in China

Demonstrated a statistically significant extension in the study’s primary endpoint of progression free survival (PFS) over the comparator treatment, vinorelbine

Plan to submit in 1H FY2016

Investigate clinical effect in triple negative breast cancer in combination with immune checkpoint inhibitor*3
Phase II part of Phase Ib/II study ongoing

*1: Overall survival
*2: Approved indication in U.S. and EU: advanced liposarcoma. Approved indication in Japan: soft tissue sarcoma
*3: Anti-PD-1 antibody pembrolizumab
Lenvima

Value maximization through potential new indication for renal cell carcinoma and submission for hepatocellular carcinoma

Renal cell carcinoma 2\textsuperscript{nd} line in combination with everolimus

U.S.: PDUFA\textsuperscript{*1} action date anticipated on May 16, 2016

EU: Approval anticipated in 1H FY2016

Aim to provide new treatment option for patients with renal cell carcinoma, which remained significant unmet medical needs for low 5-year survival rates

Hepatocellular carcinoma 1\textsuperscript{st} line

Phase III study ongoing and global submission anticipated in FY2016

Combination regimens with immune checkpoint inhibitor\textsuperscript{*2}

Phase II part of Phase Ib/II study ongoing

- All 6 types of tumors proceeded to Phase II part with fixed dose from confirmed combinability and clinical activities

- Plan to present the results of Phase Ib part at major conference

Lung cancer, melanoma, head and neck cancer, bladder cancer, renal cell carcinoma and endometrial cancer

Biliary tract cancer 2\textsuperscript{nd} line

Phase II study ongoing in Japan

Endometrial cancer

Phase IIb study under preparation

\textsuperscript{*1} Prescription Drug User Fee Act

\textsuperscript{*2} Anti-PD-1 antibody pembrolizumab
Americas Region Management

- Aim to expand B to B and accelerate Access to medical community such as IDN, ACO and others by focusing on community/regional healthcare
- Deliver holistic solutions considering characteristics of each medical community and changes in medical needs through collaboration between R&D group, Medical group, Access team and sales force

Establishment of End to End organization

- Neurology Business Group (NBG)
- Oncology Business Group (OBG)

- Develop Early Decision and Scientific Acumen in End to End organization with integration of Discovery, Clinical and Commercial

Strengthen Talent

- Allocate executives of NBG and OBG in U.S.
  5 out of 7 NBG executives and 3 of 5 OBG executives are allocated in U.S.
- Americas region president also holds the post of NBG president
  Maximize each function in NBG and OBG in U.S. as an End to End organization with collaboration between executives
- Three new members of senior management*1 joined in April 2016

Revenue of Americas (millions USD)

- 1,124 millions USD
  110% YoY
- 1,018 millions USD

FY2015 Results

- Global brands total 294
- Other products 723

FY2016 Forecast

Aim to grow over 450 millions USD

*1: US Commercial Head of NBG, Commercial Development Head of NBG and Head of Americas Medical Affairs
*2: Business to Business  *3: Integrated Delivery Networks  *4: Accountable Care Organization
New Deployment of Japan Region

Medical - Outcome - Access
- Realize novel value provision for customers through creation of real world data and pursuit of Outcome beyond treatment efficacy

Integrated Product Package
- Initiate establishment of new business model aiming for maximization of Outcome through integration of branded drugs*1, long-listed drugs and generics

Home Care Market (community/regional healthcare)
- Aim to contribute to community/regional healthcare through outreach to healthcare supporting pharmacies, ‘Corporation of Regional Medical Collaboration’*2 and others

EA Pharma*3
- Early maximization of synergic effect from integration of Eisai’s gastrointestinal disease business and AJINOMOTO PHARMACEUTICALS CO., LTD.

ICT Driven Innovation
- Establish ICT environment to realize integration and smartification of big data
- Create innovation efficiently and effectively through analysis of big data, including real world data and integration to business and strategies

Dementia solutions
- Provide solutions leveraging accumulated dementia assets
- Aim to initiate Multidisciplinary coordination system in 1H FY2016

*1: The products designated by MHLW as Premium to promote the development of new drugs and eliminate off-label use (products re-priced by marketing expansion are included); Halaven, Lenvima, Treakisym, Gliadel, Humira, Lyrica, Lunesta, Careram, Fostoin, Inovelon, Maxalt, NerBloc and Lipacreon
*2: Establishment planned by MHLW in FY2017
*3: Establishment on April 1, 2016
*4: Approved for indication of adjunctive therapy for partial-onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs on March 28, 2016. Currently under preparation for launch.
*5: FY2015 results include diagnostics business, and FY2016 forecast includes EA Pharma
Progress of the flagship pipeline of 13 "Ricchi" and Innovation

**Neurology: 6 "Ricchi"**

- **E2609**
  - BACE inhibitor
  - Early AD

- **BAN2401**
  - Anti-A-beta protofibrils antibody
  - Early AD

- **Aducanumab**
  - Anti-A-beta antibody
  - Early AD

- **Lemborexant**
  - Orexin receptor antagonist
  - Insomnia and sleep-wake fragmentation in dementia

- **E2027**
  - PDE9 inhibitor
  - Dementia

**Oncology: 4 "Ricchi"**

- **E6011**
  - Anti-fractalkine antibody
  - Rheumatoid arthritis and Crohn's disease

- **Halaven**
  - Breast cancer and STS
  - Confirmed MET (mesenchymal epithelial transition) inducing effect which has not been confirmed in bevacizumab, in clinical data in patient with breast cancer
  - Seek further potential indications as microenvironment modulator

- **FGFR4 Inhibitor**
  - HCC
  - Initiation of Phase I planned in 1H FY2016

- **SF3B1 Modulator**
  - Myeloid Malignancies
  - Initiation of Phase I planned in 1H FY2016
  - Confirmed activity in human leukemia transplanted animal model with the spliceosomal gene mutation

**LENVIMA**

- VEGF/FGFR/RET kinase inhibitor
- Thyroid cancer: Globally launched in 2015
  - Renal cell carcinoma in combination with everolimus:
    - U.S. PDUFA action date anticipated on May 16, 2016
    - EU approval anticipated in 1H FY2016
  - Hepatocellular carcinoma:
    - Phase III ongoing
    - Global submission planned in FY2016
    - Combination therapy with immune checkpoint inhibitor:
      - Phase II part of Phase Ib/II ongoing
      - Biliary tract cancer: Phase II ongoing
      - Endometrial cancer: Phase Ib under preparation

---

Financial Integrity to Ensure Continued Strategic Investments and Stable Dividend

Strategic investments
- Growth of global brands
- Acceleration of product creation
- M&A and partnerships

Stable dividend policy
- Maintain 150 yen dividend
  - DOE*1 8% level

- Debt capacity
  - 200B yen level

- Investment selection standard
  - VCIC*2 to ensure value creation

Financial Integrity

- Changes in Net DER*3 and ratio of equity attributable to owners of the parent

- Changes in free cash flow and total dividend payment (billion yen)

Strong Balance Sheet
- Ample Cash Flow

Seek sustainable shareholder value creation

Dividend per share subject to resolution of Board of Directors  
*FY2012 results according to J-GAAP; results from FY2013 onward according to IFRS
*1: Dividend on Equity  
*2: Value Creative Investment Criteria
*3: Net DER = (Interest-bearing debts[Bonds and borrowings] - Cash and cash equivalents - Time deposits exceeding three months) / Equity attributable to owners of the parent
## Forecast for FY2016 (IFRS)

(Billion yen, %)

<table>
<thead>
<tr>
<th></th>
<th>FY2015</th>
<th>%</th>
<th>FY2016</th>
<th>%</th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>547.9</td>
<td>100.0</td>
<td>580.0</td>
<td>100.0</td>
<td>106</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>194.5</td>
<td>35.5</td>
<td>210.5</td>
<td>36.3</td>
<td>108</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>353.5</td>
<td>64.5</td>
<td>369.5</td>
<td>63.7</td>
<td>105</td>
</tr>
<tr>
<td><strong>R&amp;D expenses</strong></td>
<td>122.3</td>
<td>22.3</td>
<td>124.2</td>
<td>21.4</td>
<td>102</td>
</tr>
<tr>
<td><strong>SG&amp;A expenses</strong></td>
<td>192.8</td>
<td>35.2</td>
<td>196.9</td>
<td>33.9</td>
<td>102</td>
</tr>
<tr>
<td><strong>Other income &amp; expenses</strong></td>
<td>13.6</td>
<td>2.5</td>
<td>5.3</td>
<td>0.9</td>
<td>39</td>
</tr>
<tr>
<td><strong>Operating profit</strong></td>
<td>51.9</td>
<td>9.5</td>
<td>53.7</td>
<td>9.3</td>
<td>103</td>
</tr>
<tr>
<td><strong>Profit for the year</strong></td>
<td>55.0</td>
<td>10.0</td>
<td>32.4</td>
<td>5.6</td>
<td>59</td>
</tr>
<tr>
<td><strong>Profit for the year</strong></td>
<td>54.9</td>
<td>10.0</td>
<td>29.2</td>
<td>5.0</td>
<td>53</td>
</tr>
<tr>
<td><strong>(attributable to owners of the parent)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS (yen)</strong></td>
<td>192.2</td>
<td></td>
<td>102.1</td>
<td></td>
<td>53</td>
</tr>
<tr>
<td><strong>ROE (%)</strong></td>
<td>9.4</td>
<td></td>
<td>5.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DOE (%)</strong></td>
<td>7.3</td>
<td></td>
<td>7.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dividends (yen)</strong></td>
<td>150</td>
<td></td>
<td>150</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**The year for growth in all regions**


Reference Data
## Revenue by Reporting Segment

(Billion yen, %)

<table>
<thead>
<tr>
<th></th>
<th>FY2014</th>
<th>FY2015</th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Results</td>
<td>%</td>
<td>Results</td>
</tr>
<tr>
<td>Japan*1</td>
<td>278.4</td>
<td>50.8</td>
<td>266.8</td>
</tr>
<tr>
<td>Americas*2</td>
<td>119.8</td>
<td>21.8</td>
<td>122.2</td>
</tr>
<tr>
<td>China</td>
<td>41.0</td>
<td>7.5</td>
<td>49.3</td>
</tr>
<tr>
<td>Asia*3</td>
<td>30.9</td>
<td>5.6</td>
<td>34.0</td>
</tr>
<tr>
<td>EMEA*4</td>
<td>38.5</td>
<td>7.0</td>
<td>41.3</td>
</tr>
<tr>
<td>Consumer Healthcare Business (Japan)*5</td>
<td>17.0</td>
<td>3.1</td>
<td>18.1</td>
</tr>
<tr>
<td>Pharmaceutical Business Total</td>
<td>525.7</td>
<td>95.8</td>
<td>531.8</td>
</tr>
<tr>
<td>Other</td>
<td>22.8</td>
<td>4.2</td>
<td>16.2</td>
</tr>
<tr>
<td>Consolidated revenue</td>
<td>548.5</td>
<td>100.0</td>
<td>547.9</td>
</tr>
</tbody>
</table>

Pharmaceutical Businesses of Japan, Americas, China, Asia, and EMEA

*1: Prescription medicines, generics, and diagnostics  
*2: North, Central, and South America  
*3: Mainly South Korea, Taiwan, Hong Kong, India, and ASEAN  
*4: Europe, the Middle East, Africa, Russia, and Oceania  
*5: Mainly OTC products
## Profit by Reporting Segment

(Billion yen, %)

<table>
<thead>
<tr>
<th></th>
<th>FY2014</th>
<th></th>
<th></th>
<th>FY2015</th>
<th></th>
<th></th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Results</td>
<td>%</td>
<td>% of revenue</td>
<td>Results</td>
<td>%</td>
<td>% of revenue</td>
<td></td>
</tr>
<tr>
<td>Japan*1</td>
<td>122.4</td>
<td>71.6</td>
<td>44.0</td>
<td>111.6</td>
<td>64.5</td>
<td>41.8</td>
<td>91</td>
</tr>
<tr>
<td>Americas*2</td>
<td>14.9</td>
<td>8.7</td>
<td>12.4</td>
<td>23.7</td>
<td>13.7</td>
<td>19.4</td>
<td>159</td>
</tr>
<tr>
<td>China</td>
<td>10.6</td>
<td>6.2</td>
<td>25.8</td>
<td>12.9</td>
<td>7.5</td>
<td>26.2</td>
<td>122</td>
</tr>
<tr>
<td>Asia*3</td>
<td>7.4</td>
<td>4.3</td>
<td>24.0</td>
<td>8.3</td>
<td>4.8</td>
<td>24.4</td>
<td>112</td>
</tr>
<tr>
<td>EMEA*4</td>
<td>6.6</td>
<td>3.9</td>
<td>17.1</td>
<td>10.3</td>
<td>6.0</td>
<td>25.0</td>
<td>156</td>
</tr>
<tr>
<td>Consumer Healthcare Business (Japan)*5</td>
<td>1.3</td>
<td>0.8</td>
<td>7.7</td>
<td>2.7</td>
<td>1.6</td>
<td>14.9</td>
<td>205</td>
</tr>
<tr>
<td><strong>Pharmaceutical Business Total</strong></td>
<td><strong>163.2</strong></td>
<td><strong>95.5</strong></td>
<td><strong>31.0</strong></td>
<td><strong>169.6</strong></td>
<td><strong>98.0</strong></td>
<td><strong>31.9</strong></td>
<td><strong>104</strong></td>
</tr>
<tr>
<td>Other Business</td>
<td>7.8</td>
<td>4.5</td>
<td>34.1</td>
<td>3.5</td>
<td>2.0</td>
<td>21.4</td>
<td>44</td>
</tr>
<tr>
<td><strong>Total segment profit</strong></td>
<td><strong>170.9</strong></td>
<td><strong>100.0</strong></td>
<td><strong>31.2</strong></td>
<td><strong>173.1</strong></td>
<td><strong>100.0</strong></td>
<td><strong>31.6</strong></td>
<td><strong>101</strong></td>
</tr>
<tr>
<td>R&amp;D Expenses and Group headquarter’s management costs and other expenses</td>
<td>(142.6)</td>
<td></td>
<td></td>
<td>(136.2)</td>
<td></td>
<td></td>
<td>96</td>
</tr>
<tr>
<td>Gain on sales of subsidiaries*6</td>
<td></td>
<td></td>
<td></td>
<td>15.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Consolidated operating profit</strong></td>
<td><strong>28.3</strong></td>
<td><strong>5.2</strong></td>
<td></td>
<td><strong>51.9</strong></td>
<td><strong>9.5</strong></td>
<td></td>
<td><strong>183</strong></td>
</tr>
</tbody>
</table>

**Pharmaceutical Business of Japan, Americas, China, Asia and EMEA**

*1: Prescription medicines, generics and diagnostics *2: North, Central and South America *3: Mainly South Korea, Taiwan, Hong Kong, India, and ASEAN
*4: Europe, the Middle East, Africa, Russia, and Oceania *5: Mainly OTC products *6: Transfer of shares of EIDIA Co., Ltd. in Q3 and transfer of shares of Eisai Food & Chemicals Co., Ltd. in Q4
# Performance of Japan Pharmaceutical Business

(Billion yen, %)

<table>
<thead>
<tr>
<th></th>
<th>FY2014</th>
<th></th>
<th></th>
<th>FY2015</th>
<th></th>
<th></th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Results</td>
<td>%</td>
<td></td>
<td>Results</td>
<td>%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>278.4</td>
<td>100.0</td>
<td>266.8</td>
<td>100.0</td>
<td>96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prescription medicines</td>
<td>245.5</td>
<td>88.2</td>
<td>233.9</td>
<td>87.7</td>
<td>95</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aricept</td>
<td>46.9</td>
<td>16.9</td>
<td>40.5</td>
<td>15.2</td>
<td>86</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Humira</td>
<td>29.9</td>
<td>10.7</td>
<td>32.6</td>
<td>12.2</td>
<td>109</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pariet*1</td>
<td>37.1</td>
<td>13.3</td>
<td>30.4</td>
<td>11.4</td>
<td>82</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lyrica*2</td>
<td>21.5</td>
<td>7.7</td>
<td>24.7</td>
<td>9.3</td>
<td>115</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methycobal</td>
<td>22.4</td>
<td>8.0</td>
<td>20.8</td>
<td>7.8</td>
<td>93</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warfarin</td>
<td>8.6</td>
<td>3.1</td>
<td>7.6</td>
<td>2.9</td>
<td>88</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Halaven</td>
<td>6.1</td>
<td>2.2</td>
<td>6.8</td>
<td>2.5</td>
<td>112</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actonel</td>
<td>6.7</td>
<td>2.4</td>
<td>6.4</td>
<td>2.4</td>
<td>96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lunesta</td>
<td>4.5</td>
<td>1.6</td>
<td>6.0</td>
<td>2.2</td>
<td>132</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selbex</td>
<td>4.7</td>
<td>1.7</td>
<td>3.8</td>
<td>1.4</td>
<td>81</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lenvima</td>
<td></td>
<td></td>
<td>1.5</td>
<td>0.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Generics</td>
<td>26.9</td>
<td>9.7</td>
<td>28.5</td>
<td>10.7</td>
<td>106</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnostics</td>
<td>6.0</td>
<td>2.1</td>
<td>4.4</td>
<td>1.6</td>
<td>74</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Segment profit*3</td>
<td>122.4</td>
<td>44.0</td>
<td>111.6</td>
<td>41.8</td>
<td>91</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*1: The revenue for Pariet includes the revenue for triple formulation packs for *Helicobacter pylori* eradication packs, Rabecure Pack 400/800 and Rabefine Pack.
*2: Alliance revenue.
*3: From the consolidated fiscal year ending March 31, 2016, the management structure for part of the costs in Japan was revised and the method for allocation of SG&A expenses changed as a result. As such, the “Japan pharmaceutical business” and “Consumer Healthcare Business—Japan” segment profit (loss) as well as “Group headquarters” management costs and other expenses” management costs and other expenses” figures stated for the previous fiscal year ended March 31, 2015, have also been restated to reflect changes.
## Performance of Americas Pharmaceutical Business

(billion yen, %)

<table>
<thead>
<tr>
<th></th>
<th>FY2014</th>
<th></th>
<th>FY2015</th>
<th></th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Results</td>
<td>%</td>
<td>Results</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>119.8</td>
<td>100.0</td>
<td>122.2</td>
<td>100.0</td>
<td>102 [93]</td>
</tr>
<tr>
<td>Aloxi</td>
<td>49.8</td>
<td>41.6</td>
<td>54.7</td>
<td>44.7</td>
<td>110 [100]</td>
</tr>
<tr>
<td>Halaven</td>
<td>16.5</td>
<td>13.8</td>
<td>18.3</td>
<td>15.0</td>
<td>111 [103]</td>
</tr>
<tr>
<td>Banzel</td>
<td>10.4</td>
<td>8.7</td>
<td>13.2</td>
<td>10.8</td>
<td>127 [116]</td>
</tr>
<tr>
<td>Lenvima</td>
<td>0.4</td>
<td>0.3</td>
<td>8.8</td>
<td>7.2</td>
<td>2327 [2129]</td>
</tr>
<tr>
<td>AcipHex</td>
<td>11.7</td>
<td>9.8</td>
<td>8.3</td>
<td>6.8</td>
<td>71 [65]</td>
</tr>
<tr>
<td>BELVIQ®</td>
<td>5.4</td>
<td>4.5</td>
<td>4.4</td>
<td>3.6</td>
<td>81 [74]</td>
</tr>
<tr>
<td>Fycompa</td>
<td>1.9</td>
<td>1.6</td>
<td>3.8</td>
<td>3.1</td>
<td>206 [190]</td>
</tr>
<tr>
<td>Segment profit</td>
<td>14.9</td>
<td>12.4</td>
<td>23.7</td>
<td>19.4</td>
<td>159 [142]</td>
</tr>
</tbody>
</table>

[ ] based on local currency
## Performance of China and Asia Pharmaceutical Business

### <China>

<table>
<thead>
<tr>
<th></th>
<th>FY2014 Results</th>
<th>FY2015 Results</th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>41.0</td>
<td>49.3</td>
<td>120</td>
</tr>
<tr>
<td>Methycobal</td>
<td>17.3</td>
<td>18.7</td>
<td>108</td>
</tr>
<tr>
<td>Stronger Neo-Minophagen C/ Glycyron Tablets</td>
<td>6.9</td>
<td>9.3</td>
<td>134</td>
</tr>
<tr>
<td>Aricept</td>
<td>4.7</td>
<td>5.6</td>
<td>118</td>
</tr>
<tr>
<td>Pariet</td>
<td>2.9</td>
<td>3.3</td>
<td>114</td>
</tr>
<tr>
<td>Segment profit</td>
<td>10.6</td>
<td>12.9</td>
<td>122</td>
</tr>
</tbody>
</table>

* [] based on local currency

### <Asia*>

<table>
<thead>
<tr>
<th></th>
<th>FY2014 Results</th>
<th>FY2015 Results</th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>30.9</td>
<td>34.0</td>
<td>110</td>
</tr>
<tr>
<td>Aricept</td>
<td>9.4</td>
<td>10.0</td>
<td>107</td>
</tr>
<tr>
<td>Humira</td>
<td>8.1</td>
<td>9.0</td>
<td>111</td>
</tr>
<tr>
<td>Pariet</td>
<td>3.7</td>
<td>3.5</td>
<td>96</td>
</tr>
<tr>
<td>Methycobal</td>
<td>2.6</td>
<td>3.1</td>
<td>118</td>
</tr>
<tr>
<td>Halaven</td>
<td>1.2</td>
<td>1.9</td>
<td>161</td>
</tr>
<tr>
<td>Segment profit</td>
<td>7.4</td>
<td>8.3</td>
<td>112</td>
</tr>
</tbody>
</table>

* *Mainly South Korea, Taiwan, Hong Kong, India, and ASEAN

* [] based on local currency
### Performance of EMEA Pharmaceutical Business and Consumer Healthcare Business (mainly OTC products)

#### <EMEA*>

<table>
<thead>
<tr>
<th></th>
<th>FY2014</th>
<th></th>
<th>FY2015</th>
<th></th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Results</td>
<td>%</td>
<td>Results</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>38.5</td>
<td>100.0</td>
<td>41.3</td>
<td>100.0</td>
<td>107</td>
</tr>
<tr>
<td>Halaven</td>
<td>11.6</td>
<td>30.0</td>
<td>13.2</td>
<td>31.9</td>
<td>114</td>
</tr>
<tr>
<td>Zonegran</td>
<td>8.1</td>
<td>21.1</td>
<td>7.6</td>
<td>18.5</td>
<td>94</td>
</tr>
<tr>
<td>Zebinix</td>
<td>3.2</td>
<td>8.4</td>
<td>3.8</td>
<td>9.3</td>
<td>118</td>
</tr>
<tr>
<td>Fycompa</td>
<td>2.4</td>
<td>6.2</td>
<td>3.6</td>
<td>8.8</td>
<td>151</td>
</tr>
<tr>
<td>Inovelon</td>
<td>2.1</td>
<td>5.5</td>
<td>2.2</td>
<td>5.3</td>
<td>103</td>
</tr>
<tr>
<td>Lenvima</td>
<td></td>
<td></td>
<td>1.1</td>
<td>2.7</td>
<td></td>
</tr>
<tr>
<td>Segment profit</td>
<td>6.6</td>
<td>17.1</td>
<td>10.3</td>
<td>25.0</td>
<td>156</td>
</tr>
</tbody>
</table>

*Europe, the Middle East, Africa, Russia, and Oceania

[ ] based on local currency

#### <Consumer Healthcare Business (Japan)>

<table>
<thead>
<tr>
<th></th>
<th>FY2014</th>
<th></th>
<th>FY2015</th>
<th></th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result</td>
<td>%</td>
<td>Results</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>17.0</td>
<td>100.0</td>
<td>18.1</td>
<td>100.0</td>
<td>106</td>
</tr>
<tr>
<td>Chocola BB Group</td>
<td>10.3</td>
<td>60.8</td>
<td>11.1</td>
<td>61.1</td>
<td>107</td>
</tr>
<tr>
<td>Segment profit*</td>
<td>1.3</td>
<td>7.7</td>
<td>2.7</td>
<td>14.9</td>
<td>205</td>
</tr>
</tbody>
</table>

* From the consolidated fiscal year ending March 31, 2016, the management structure for part of the costs in Japan was revised and the method for allocation of SG&A expenses changed as a result. As such, the “Japan pharmaceutical business” and “Consumer Healthcare Business—Japan” segment profit (loss) as well as “Group headquarters” management costs and other expenses” management costs and other expenses” figures stated for the previous fiscal year ended March 31, 2015, have also been restated to reflect changes.